Rovalpituzumab tesirine

From WikiMD.org
Jump to navigation Jump to search

Rovalpituzumab tesirine (pronunciation: roh-val-pi-TOO-zoo-mab te-SEER-een) is a monoclonal antibody-drug conjugate designed for the treatment of small cell lung cancer (SCLC).

Etymology

The name "Rovalpituzumab tesirine" is derived from the components of the drug. "Rova" refers to the targeting component, a monoclonal antibody that binds to delta-like protein 3 (DLL3), "pituzu" is a stem used in World Health Organization (WHO) International Nonproprietary Names (INN) for monoclonal antibodies, and "mab" indicates that it is a monoclonal antibody. "Tesirine" refers to the cytotoxic agent that is conjugated to the antibody.

Mechanism of Action

Rovalpituzumab tesirine works by binding to the DLL3 protein, which is overexpressed in SCLC. Once bound, the drug is internalized into the cancer cell where the cytotoxic agent is released, causing cell death.

Related Terms

See Also

External links

Esculaap.svg

This WikiMD dictionary article is a stub. You can help make it a full article.


Languages: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski